drugset / Trial / NCT03069937
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to look at patient outcomes when docetaxel is started prior to ADT with degarelix.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2021-03-03
- Completion
- 2024-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 80 mg | Subcutaneous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |